TY - JOUR T1 - Review: infliximab increases response and remission rates in fistulising or treatment-resistant Crohn’s disease JF - Evidence Based Medicine JO - Evid Based Med SP - 186 LP - 186 DO - 10.1136/ebm.7.6.186 VL - 7 IS - 6 A2 - , Y1 - 2002/11/01 UR - http://ebm.bmj.com/content/7/6/186.abstract N2 - ; Marshall JK, Blackhouse G, Goeree R, et al.Infliximab for the treatment of Crohn’s disease: a systematic review and cost-utility analysis. Technology report no. 24. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2002. http://www.ccohta.ca..
 
 QUESTION: In patients with fistulising or treatment-resistant Crohn’s disease, is infliximab safe and effective? Studies were identified by searching Medline, EMBASE/Excerpta Medica, Current Contents, CINAHL, HealthSTAR, TOXLINE, the Cochrane Library, Drug Info Full Text, Pharmaceutical & Health Care Industry News, PharmaProjects, and Pharmaceutical News Index (1990 to May 2001). Scientific meeting abstracts were searched; major clinical gastroenterology journals were hand searched (to August 2001); and authors, government agencies, and pharmaceutical companies were contacted. 2 reviewers independently selected English-language randomised controlled trials (RCTs) that reported clinical end points for infliximab treatment in adults with fistulising or treatment-resistant Crohn’s disease. 2 independent reviewers extracted data on study centres, source of funding, … ER -